Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

E. Gray, Jhanelle; Villegas, Augusto; B. Daniel, Davey; Vicente, David; Murakami, Shuji; Hui, Rina; Kurata, Takayasu; Chiappori, Alberto; Hyeong Lee, Ki; Chul Cho, Byoung; Planchard, David; Paz‐Ares, Luis; Faivre‐Finn, Corinne; Vansteenkiste, Johan; R. Spigel, David; Wadsworth, Catherine; Taboada, Maria; A. Dennis, Phillip; Özgüroğlu, Mustafa; Antonia, Scott

doi:10.1016/j.jtho.2019.10.002

Public

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

Published in Journal of Thoracic Oncology • Oct 14, 2019

Authors:

Jhanelle E. Gray

Augusto Villegas

Davey B. Daniel

Abstract

INTRODUCTION: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence inter...

Subject

Durvalumab

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!